D. / Salix Pharmaceuticals Inc. / Salix Pharmaceuticals / M.D. (Acting) Deputy / /
Currency
pence / /
Event
FDA Phase / /
Facility
Northwestern University / Hepatology Indiana University / UCSF Liver Transplant Program University of California / /
MedicalCondition
hepatic encephalopathy / severe liver disease / /
Organization
Gastrointestinal Drugs Advisory Committee / Division of Gastroenterology / School of Medicine Efficacy of Rifaximin for Treatment / U.S. Food and Drug Administration / Northwestern University / Feinberg School / Center for Drug Evaluation and Research / University of California / San Francisco / Division of Hepatology / Indiana University / /
Person
Kristine Khuc / Nathan Bass / David Dobrowski / Hepatic Encephalopathy William Forbes / Pamela Golden / Efficacy Lara Dimick / Jean-Pierre Raufman / Steven Flamm / Review Insook Kim / William Forbes / Ranjit Mani / Remarks Ruyi He / /
Position
Director / Regulatory Affairs / Director of Liver Transplantation and Professor of Medicine / Professor and Director / Professor of Medicine and Associate Medical Director / Medical Officer / Division of Neurology Products / Director / Medical Director / Designated Federal Official / Professor of Medicine and Surgery / Director / Development / Senior Vice President / Research and Development Chief Development Officer / Medical Officer / /
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only. This content has not been altered or updated since it was archived